The goal of cancer treatment is to kill tumor cells. However, the natural process of eliminating necrotic cells in the body actually accelerates tumor growth. A study by the University of Michigan in the United States identified this rarely understood behavioral pathway in metastatic prostate cancer cells, helping to develop new drugs that block the accelerated growth of harmful tumors while also eliminating dead cells. . This process of removing cell debris is called burial and is a critical function for both healthy and cancer patients. The study found that in metastatic prostate cancer cells, the burial process produces a pro-inflammatory protein called CXCL5 that stimulates tumor growth. When the researchers induced cell death in mouse bone tumors, they were associated with an increase in CXCL5 protein, and tumor cell growth accelerated when induced cell death accelerated. However, tumor growth was impeded when CXCL5 protein was blocked in mice. The researchers will also study blood samples from patients with metastatic prostate cancer and find that their CXCL5 protein levels are higher than those in healthy and localized prostate cancer patients. Researchers say that uncontrolled cell growth is accompanied by a significant number of cancer cell deaths, and that removing dead cells while avoiding the accelerated growth of pro-inflammatory proteins and tumor cells is a new challenge. The study, entitled "Induction of CXCL5 by Apoptosis to Accelerate Inflammation and Growth of Prostate Cancer Bone Metastasis," was published in the November 27, 2017 issue of Clinical Research. (Technology Daily) Drug intermediates,Pharmaceutical intermediates,Intermediates APIS NANYANG CHENGPENG PHARMACEUTICAL CO.,LTD , https://www.chppharm.com